<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02566733</url>
  </required_header>
  <id_info>
    <org_study_id>Remifentanil_CPB</org_study_id>
    <nct_id>NCT02566733</nct_id>
  </id_info>
  <brief_title>Minto Model in Effect Site Mode for Target-Controlled Infusion of Remifentanil During Cardiopulmonary Bypass</brief_title>
  <official_title>Performance of the Minto Model in Effect Site Mode for Target Controlled Infusion of Remifentanil During Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Target controlled infusion with remifentanil is widely used during cardiac surgery, wich is
      performed using the Minto model. It was derived from patients undergoing general surgery.
      However, pharmacokinetics of remifentanil can be changed during cardiopulmonary bypass. The
      investigators tested whether Minto model for target controlled infusion produces constant
      plasma remifentanil concentration during the cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median prediction error</measure>
    <time_frame>during CPB</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of measured total remifentanil concentration</measure>
    <time_frame>1 hour after anesthesia induction, 30/60/90 min after the beginning of cardiopulmonary bypass, 1 hour after the end of cardiopulmonary bypass</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median absolute prediction error</measure>
    <time_frame>during CPB</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Anesthetics, Intravenous</condition>
  <condition>Pharmacology</condition>
  <condition>Anesthetics</condition>
  <condition>Cardiopulmonary Bypass</condition>
  <arm_group>
    <arm_group_label>Remiva</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This experimental group will use a generic drug of remifentanil, Remiva™ from Hana Pharmaceutical company.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultiva</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm group will use a brand-named drug of remifentanil, Ultiva™ from GlaxoSmithKline company.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remiva</intervention_name>
    <description>Target controlled infusion of remifentanil (generic drug, Remiva™)</description>
    <arm_group_label>Remiva</arm_group_label>
    <other_name>generic drug of remifentanil, Remiva™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ultiva</intervention_name>
    <description>Target controlled infusion of remifentanil (brand-named drug, Ultiva™)</description>
    <arm_group_label>Ultiva</arm_group_label>
    <other_name>brand-named drug of remifentanil, Ultiva™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with the ASA class I~III undergoing elective cardiac surgery using
             cardiopulmonary bypass

        Exclusion Criteria:

          -  Patients not using target controlled infusion during the operation

          -  Patients with drug/substance abuse

          -  Patients using analgesics before this study starts

          -  Pregnant women

          -  Patients who rejected study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae Kyong Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Tae Kyong Kim</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>remifentanil</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

